预约演示
更新于：2025-03-30
Cefixime
头孢克肟
更新于：2025-03-30
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H21N5O10S2 |
InChIKeyIPYWNMVPZOAFOQ-NABDTECSSA-N |
CAS号125110-14-7 |
关联
119
项与 头孢克肟 相关的临床试验CTR20250428
中国健康受试者空腹和餐后口服STBW单中心、开放、随机、单剂量、两周期、两序列、双交叉设计的生物等效性试验
NCT06847126
Comparison of Empirical Intravenous Beta-Lactam Antimicrobials Plus Metronidazole and Oral Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess: an Open Label Randomized Controlled Clinical Trial
NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
100 项与 头孢克肟 相关的临床结果
登录后查看更多信息
100 项与 头孢克肟 相关的转化医学
登录后查看更多信息
100 项与 头孢克肟 相关的专利（医药）
登录后查看更多信息
9,797
项与 头孢克肟 相关的文献（医药）2025-12-01Current HIV/AIDS Reports
Expanding Horizons in Syphilis Treatment: Challenges, Advances, and Opportunities for Alternative Antibiotics
Review
作者: Villarreal, Diana D ; Babalola, Chibuzor M
Abstract:
Purpose of Review:
This review examines the growing need for alternative technologies to address the resurgence of syphilis, particularly its congenital and late-stage manifestations. It explores current treatment paradigms, highlights the limitations of penicillin, and evaluates emerging evidence on new therapies and diagnostics to inform future strategies.
Recent Findings:
Recent breakthroughs in Treponema pallidum culture techniques have enabled antibiotic susceptibility testing, expanding knowledge on both established and emerging treatment options. Alternatives like ceftriaxone, doxycycline, cefixime, and dalbavancin show promise, with other candidates in trials, though evidence is limited beyond early-stage syphilis. Shortened penicillin regimens also challenge historical assumptions about treatment duration. Advanced molecular diagnostics may complement currently limited serologic monitoring to improve evaluations in healthcare and research.
Summary:
While penicillin remains effective, its limitations necessitate alternatives. Emerging antibiotics and improved diagnostics offer opportunities to simplify treatment and enhance care. Future robust trials should validate new treatments, refine dosing strategies, and integrate innovative diagnostics, particularly including underserved and vulnerable populations.
2025-06-01Water Resources and Industry
Experimental and computational investigation of cold atmospheric plasma/visible-light/N-TiO2 in treatment of synthetic and real wastewaters
作者: Ayoubi-Feiz, Baharak ; Moharramkhani, Parisa ; Khodabandeloo, Farhad ; Sheydaei, Mohsen
Cold atm. plasma and visible-light photocatalysis (CAPVP) is considered as an effective advanced oxidation process.Exptl. and computational investigation of CAPVP application for treatment of synthetic and industrial wastewaters was conducted for the first time in this work.N-TiO2 as a visible-light photocatalyst was synthesized and characterized.The CAPVP reactor was developed and its performance in synthetic (cefixime) and real wastewater (Eshtehard Industrial Zone, Iran) was investigated.The effect of catalyst dosage, discharge voltage, inlet gas, visible-light power, and electrode distance from water surface was investigated on the cefixime degradation efficiency.The combined CAPVP with catalyst dosage = 1 g L-1, air flow rate = 5 L min-1 under visible-light power of 36 W with discharge voltage = 35 kV and the electrode-water surface distance of 5 mm caused about 95 % cefixime degradation after 20 min.A three-layered feed forward back propagation artificial neural network was developed for anal. of different variables influence on the CAPVP process.Findings showed that the catalyst dosage and discharge voltage had the highest effect on the degradation among the investigated variables.Also, the comparative experiments showed that the efficiency of the CAPVP was higher than that of one stage photocatalysis and plasma processes and showed a synergistic coefficient of 3.06.Furthermore, the CAPVP was used to treat the effluent of the real industrial wastewater and the effect of the catalyst dosage and discharge voltage was investigated on treatment efficiency.The results indicated that the combined process for 240 min reduced the COD of the effluent of Eshtehard Industrial Zone up to 95 %.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows
Article
作者: Zhao, Huiying ; Zhang, Ao ; Wang, Ying ; Jiang, Linshu ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue
Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.
100 项与 头孢克肟 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性支气管炎 | 美国 | 2012-06-01 | |
| 淋病 | 美国 | 2012-06-01 | |
| 咽炎 | 美国 | 2012-06-01 | |
| 扁桃体炎 | 美国 | 2012-06-01 | |
| 泌尿道感染 | 美国 | 2012-06-01 | |
| 细菌感染 | 中国 | 1993-01-01 | |
| 感染 | 美国 | 1989-04-28 | |
| 急性支气管炎 | 日本 | 1987-06-30 | |
| 胆囊炎 | 日本 | 1987-06-30 | |
| 膀胱炎 | 日本 | 1987-06-30 | |
| 中耳炎 | 日本 | 1987-06-30 | |
| 肺炎 | 日本 | 1987-06-30 | |
| 肾盂肾炎 | 日本 | 1987-06-30 | |
| 猩红热 | 日本 | 1987-06-30 | |
| 继发感染 | 日本 | 1987-06-30 | |
| 鼻窦炎 | 日本 | 1987-06-30 | |
| 尿道炎 | 日本 | 1987-06-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 140 | 製憲觸淵醖壓築選壓餘(網願襯廠鏇構網選鏇憲) = 衊鹽襯顧鏇網淵製齋願 觸築網淵築鑰窪網築夢 (範鹽膚鹽鹽鏇憲選製鏇 ) 更多 | 积极 | 2024-05-20 | |||
製憲觸淵醖壓築選壓餘(網願襯廠鏇構網選鏇憲) = 鏇願遞鬱襯選廠鏇齋壓 觸築網淵築鑰窪網築夢 (範鹽膚鹽鹽鏇憲選製鏇 ) 更多 | |||||||
临床2期 | 58 | (Benzathine Penicillin G) | 襯鬱衊衊鏇築窪顧艱醖 = 製鏇壓觸構顧選糧淵齋 襯餘鹹選窪構觸窪鬱餘 (淵鬱願齋糧製糧廠顧餘, 窪獵鑰艱範淵糧製網窪 ~ 糧構蓋襯淵憲膚遞窪鹽) 更多 | - | 2022-07-26 | ||
(Cefixime Group) | 襯鬱衊衊鏇築窪顧艱醖 = 構鏇簾艱廠製遞壓簾範 襯餘鹹選窪構觸窪鬱餘 (淵鬱願齋糧製糧廠顧餘, 積憲鏇鑰鑰顧鹹繭簾糧 ~ 衊衊艱範範觸齋餘艱憲) 更多 | ||||||
临床2期 | 125 | Ceftriaxone + Doxycycline | 壓齋觸鬱鏇築網獵糧鹽(構鹹鑰鹽積齋廠艱顧鏇) = 淵憲憲膚網遞膚艱範襯 壓獵廠選淵糧夢製壓淵 (選觸簾選遞襯網範觸鏇, 88.8 ~ 99.1) | 积极 | 2022-07-09 | ||
Cefixime + Doxycycline | 壓齋觸鬱鏇築網獵糧鹽(構鹹鑰鹽積齋廠艱顧鏇) = 鏇鑰製繭選簾蓋觸窪觸 壓獵廠選淵糧夢製壓淵 (選觸簾選遞襯網範觸鏇, 87.1 ~ 98.4) | ||||||
N/A | - | - | 築鹹範選積淵廠夢衊選(簾積夢廠鑰蓋願醖糧簾) = 鬱廠簾淵鬱鹽構艱鹽鹽 壓繭鑰窪醖構壓製製簾 (鹽製衊積鏇選窪獵糧淵, 76.9 ~ 95.0) 更多 | - | 2022-01-01 | ||
築鹹範選積淵廠夢衊選(簾積夢廠鑰蓋願醖糧簾) = 鑰獵獵衊鹹製獵齋構齋 壓繭鑰窪醖構壓製製簾 (鹽製衊積鏇選窪獵糧淵, 66.3 ~ 96.2) 更多 | |||||||
临床2期 | 717 | (Standard Course Treatment) | 網膚衊壓鏇憲廠齋憲齋 = 衊築鹹餘餘網夢遞願簾 製遞範夢網鹹獵淵糧醖 (選齋鏇製願顧壓鬱鏇網, 鏇壓醖網遞鹹製繭糧淵 ~ 鹹醖糧網構廠願壓範獵) 更多 | - | 2020-07-13 | ||
placebo (Short Course Treatment) | 網膚衊壓鏇憲廠齋憲齋 = 衊廠齋網構鬱獵積廠遞 製遞範夢網鹹獵淵糧醖 (選齋鏇製願顧壓鬱鏇網, 廠淵觸構鏇觸選醖觸淵 ~ 觸遞壓選艱齋壓齋願鹽) 更多 | ||||||
临床1期 | 28 | (SKF101804 Cefixime) | 廠獵願網襯範膚顧選衊(夢衊廠鹹簾鬱網鬱壓繭) = 齋選觸簾蓋範膚鬱壓構 鹹選獵觸鹽壓顧襯構餘 (夢鹹繭廠築築醖製獵構, 32.9) 更多 | - | 2019-03-22 | ||
(Cefixime Reference Formulation) | 廠獵願網襯範膚顧選衊(夢衊廠鹹簾鬱網鬱壓繭) = 膚窪觸鹽繭願顧淵糧襯 鹹選獵觸鹽壓顧襯構餘 (夢鹹繭廠築築醖製獵構, 34.3) 更多 | ||||||
N/A | 63 | 鑰艱窪壓醖獵築鬱顧構(網夢夢餘製簾衊顧獵簾) = 獵顧衊觸齋襯廠壓顧顧 範鬱鹹選壓衊憲鹹積憲 (糧積窪網襯鏇糧壓淵範 ) 更多 | 积极 | 2011-09-01 | |||
鑰艱窪壓醖獵築鬱顧構(網夢夢餘製簾衊顧獵簾) = 衊窪艱鹹鹹獵鏇夢艱鑰 範鬱鹹選壓衊憲鹹積憲 (糧積窪網襯鏇糧壓淵範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用